JP2001524940A5 - - Google Patents

Download PDF

Info

Publication number
JP2001524940A5
JP2001524940A5 JP1998530973A JP53097398A JP2001524940A5 JP 2001524940 A5 JP2001524940 A5 JP 2001524940A5 JP 1998530973 A JP1998530973 A JP 1998530973A JP 53097398 A JP53097398 A JP 53097398A JP 2001524940 A5 JP2001524940 A5 JP 2001524940A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP1998530973A
Other languages
English (en)
Other versions
JP2001524940A (ja
Filing date
Publication date
Priority claimed from US08/781,057 external-priority patent/US5908825A/en
Application filed filed Critical
Publication of JP2001524940A publication Critical patent/JP2001524940A/ja
Publication of JP2001524940A5 publication Critical patent/JP2001524940A5/ja
Ceased legal-status Critical Current

Links

Description

Figure 2001524940
Figure 2001524940
Figure 2001524940
Figure 2001524940
JP53097398A 1997-01-09 1998-01-09 鼻送達のための投薬組成物およびその使用方法 Ceased JP2001524940A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/781,057 1997-01-09
US08/781,057 US5908825A (en) 1997-01-09 1997-01-09 Dosage composition for nasal delivery and method of use of the same
PCT/US1998/000019 WO1998030211A1 (en) 1997-01-09 1998-01-09 Dosage composition for nasal delivery and method of use of the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2005297014A Division JP2006028199A (ja) 1997-01-09 2005-10-11 鼻送達のための投薬組成物およびその使用方法

Publications (2)

Publication Number Publication Date
JP2001524940A JP2001524940A (ja) 2001-12-04
JP2001524940A5 true JP2001524940A5 (ja) 2005-09-08

Family

ID=25121537

Family Applications (2)

Application Number Title Priority Date Filing Date
JP53097398A Ceased JP2001524940A (ja) 1997-01-09 1998-01-09 鼻送達のための投薬組成物およびその使用方法
JP2005297014A Pending JP2006028199A (ja) 1997-01-09 2005-10-11 鼻送達のための投薬組成物およびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2005297014A Pending JP2006028199A (ja) 1997-01-09 2005-10-11 鼻送達のための投薬組成物およびその使用方法

Country Status (9)

Country Link
US (1) US5908825A (ja)
EP (1) EP1028715B1 (ja)
JP (2) JP2001524940A (ja)
AT (1) ATE256460T1 (ja)
AU (1) AU5906398A (ja)
CA (1) CA2277824C (ja)
DE (1) DE69820671T2 (ja)
ES (1) ES2213267T3 (ja)
WO (1) WO1998030211A1 (ja)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9326174D0 (en) * 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
WO2002064091A2 (en) * 2001-02-13 2002-08-22 Palatin Technologies, Inc. Melanocortin metallopeptides for treatment of sexual dysfunction
CA2247388C (en) * 1996-01-25 2009-06-02 Sven-Erik Svehag Pharmaceutical composition comprising serum amyloid p component for prophylactic or therapeutic treatment of virus infections and a kit for detecting binding of compositions to virus components
US6818222B1 (en) * 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
US6579968B1 (en) * 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction
US7176279B2 (en) * 2000-06-28 2007-02-13 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US8632785B2 (en) * 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
DE60125986T3 (de) * 2000-02-08 2011-07-28 Allergan, Inc., 92612, Calif. Pharmazeutische Zusammensetzungen mit Botulinum Toxin
US20060269575A1 (en) * 2000-02-08 2006-11-30 Allergan, Inc. Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US6623765B1 (en) * 2000-08-01 2003-09-23 University Of Florida, Research Foundation, Incorporated Microemulsion and micelle systems for solubilizing drugs
US7342089B2 (en) * 2001-07-11 2008-03-11 Palatin Technologies, Inc. Cyclic peptides for treatment for cachexia
US7345144B2 (en) * 2001-07-11 2008-03-18 Palatin Technologies, Inc. Cyclic peptides for treatment of cachexia
MXPA04004726A (es) * 2001-11-19 2004-07-30 Becton Dickinson Co Composiciones farmaceuticas en forma particulada.
AU2003248888A1 (en) * 2002-07-09 2004-01-23 Palatin Technologies, Inc. Peptide composition for treatment of sexual dysfunction
WO2005010022A2 (en) * 2003-07-15 2005-02-03 University Of Maryland, Baltimore Agonist polypeptide of receptor for zot and zonulin
US20060263350A1 (en) * 2003-09-26 2006-11-23 Fairfield Clinical Trials Llc Combination antihistamine medication
US20060074025A1 (en) * 2003-12-26 2006-04-06 Nastech Pharmaceutical Company Inc. Therapeutic formulations for transmucosal administration that increase glucagon-like peptide-1 bioavailability
US20080318837A1 (en) * 2003-12-26 2008-12-25 Nastech Pharmaceutical Company Inc. Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide
US20050143303A1 (en) 2003-12-26 2005-06-30 Nastech Pharmaceutical Company Inc. Intranasal administration of glucose-regulating peptides
US20060210614A1 (en) * 2003-12-26 2006-09-21 Nastech Pharmaceutical Company Inc. Method of treatment of a metabolic disease using intranasal administration of exendin peptide
US6974187B2 (en) * 2004-01-28 2005-12-13 Tachi-S Co., Ltd. Vehicle seat structure
WO2006088491A2 (en) * 2004-06-29 2006-08-24 Massachusetts Institute Of Technology Methods and compositions related to the modulation of intercellular junctions
TW200637573A (en) * 2005-01-14 2006-11-01 Univ Maryland Peptide for delivery of mucosal vaccines
AR057058A1 (es) * 2005-06-09 2007-11-14 Alba Therapeutics Corp Metodo para usar antagonistas de zonulina para prevenir la perdida o para regenerar celulas pancreaticas
US7754691B1 (en) 2005-07-07 2010-07-13 Palatin Technologies, Inc. Linear melanocortin receptor-specific peptides for cachexia
US8247530B2 (en) * 2005-11-08 2012-08-21 Palatin Technologies, Inc. N-alkylated cyclic peptide melanocortin agonists
US20080318861A1 (en) * 2005-12-08 2008-12-25 Nastech Pharmaceutical Company Inc. Mucosal Delivery of Stabilized Formulations of Exendin
US20070232537A1 (en) * 2005-12-19 2007-10-04 Nastech Pharmaceutical Company Inc. Intranasal pyy formulations with improved transmucosal pharmacokinetics
CA2838399C (en) 2006-02-09 2017-03-07 Alba Therapeutics Corporation Formulations for a tight junction effector
US8580746B2 (en) * 2006-03-30 2013-11-12 Palatin Technologies, Inc. Amide linkage cyclic natriuretic peptide constructs
WO2007115175A2 (en) * 2006-03-30 2007-10-11 Palatin Technologies, Inc. Cyclic natriuretic peptide constructs
JP2009532385A (ja) * 2006-03-30 2009-09-10 パラティン・テクノロジーズ・インコーポレーテッド 線状ナトリウム利尿ペプチド構築物
US8728491B2 (en) * 2007-05-07 2014-05-20 Alba Therapeutics Corporation Transcutaneous delivery of therapeutic agents
WO2009015382A2 (en) 2007-07-26 2009-01-29 Alba Therapeutics Corporation Novel peptides that enhance tight junction permeability
WO2010065801A1 (en) 2008-12-04 2010-06-10 Palatin Technologies, Inc. Amine substituted piperazine melanocortin receptor-specific compounds
WO2010065799A2 (en) 2008-12-04 2010-06-10 Palatin Technologies, Inc. Amine substituted piperidine melanocortin receptor-specific compounds
WO2010065802A2 (en) 2008-12-04 2010-06-10 Palatin Technologies, Inc. Substituted pyrrolidine or imidazolidine melanocortin receptor-specific compounds
WO2010097119A1 (en) 2009-02-27 2010-09-02 Pari GmbH Spezialisten für effektive Inhalation Method for operating an aerosol inhalation device and aerosol inhalation device
MX2011013117A (es) 2009-06-08 2012-05-23 Palatin Technologies Inc Peptidos especificos del receptor de melanocortina.
EP2380618A1 (en) * 2010-04-26 2011-10-26 PARI Pharma GmbH Operating method for an aerosol delivery device and aerosol delivery device
WO2013138340A1 (en) 2012-03-13 2013-09-19 Tensive Controls Inc. Melanocortin analogs having enhanced activity and transport
CA2875384A1 (en) 2013-12-20 2015-06-20 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
US10085937B2 (en) 2014-03-14 2018-10-02 Adapt Pharma Limited Nasal drug products and methods of their use
US9561177B2 (en) 2014-03-14 2017-02-07 Adapt Pharma Limited Nasal drug products and methods of their use
CN110755372A (zh) 2014-03-14 2020-02-07 欧皮安特制药有限公司 适于经鼻递送药物产品、用于鼻内给予的药用组合物及其用途
US9480644B2 (en) 2014-03-14 2016-11-01 Opiant Pharmaceuticals, Inc. Nasal drug products and methods of their use
US10351599B2 (en) 2014-09-19 2019-07-16 Tensive Controls, Inc. Anti-microbial peptides

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5470729A (en) * 1983-03-04 1995-11-28 University Of Maryland At Baltimore Method of isolating restriction fragment deletions in Vibrio cholerae, and products thereof
US5665389A (en) * 1995-05-24 1997-09-09 University Of Maryland At Baltimore Oral dosage composition for intestinal delivery and method of treating diabetes
US5945510A (en) * 1997-05-21 1999-08-31 University Of Maryland, Baltimore Substantially pure zonulin, a physiological modulator of mammalian tight junctions

Similar Documents

Publication Publication Date Title
JP2000509635A5 (ja)
JP2000509942A5 (ja)
JP2002515801A5 (ja)
JP2000507042A5 (ja)
JP2000509912A5 (ja)
JP2000509637A5 (ja)
JP2001514650A5 (ja)
JP2002513359A5 (ja)
JP2000507433A5 (ja)
JP2000509587A5 (ja)
JP2000507369A5 (ja)
JP2000510793A5 (ja)
JP2001524940A5 (ja)
JP2000508866A5 (ja)
JP2000508022A5 (ja)
JP2000508841A5 (ja)
JP2000508680A5 (ja)
JP2000509804A5 (ja)
JP2000509755A5 (ja)
JP2002511754A5 (ja)
JP2000510969A5 (ja)
JP2000508836A5 (ja)
JP2000509520A5 (ja)
JP2001518892A5 (ja)
JP2000507434A5 (ja)